絞り込み

16507

広告

The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial.

著者 Kanozawa K , Noguchi Y , Sugahara S , Nakamura S , Yamamoto H , Kaneko K , Kono R , Sato S , Ogawa T , Hasegawa H , Katayama S
Clin Exp Nephrol.2017 Dec 23 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (219view , 0users)

Full Text Sources

We conducted the multicenter, prospective, open-label study in type 2 diabetic (T2DM) patients with renal dysfunction, to clarify the efficacy and the safety in relation to renal function and glycemic control, and the economic effect when other dipeptidyl peptidase-4 (DPP-4) inhibitors were switched to a small dose of sitagliptin depending on their renal function.
PMID: 29275488 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード